Cargando…
Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
This report represents a detailed description of experiments designed to replicate and extend the findings of a published study on the effects of treating the R6/2 Huntington’s disease (HD) mouse model with ~300 CAG repeats using the pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574864/ https://www.ncbi.nlm.nih.gov/pubmed/23437422 http://dx.doi.org/10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202 |
_version_ | 1782259651238166528 |
---|---|
author | Chen, Jane Y. Wang, Elizabeth A. Galvan, Laurie Huynh, My Joshi, Prasad Cepeda, Carlos Levine, Michael S. |
author_facet | Chen, Jane Y. Wang, Elizabeth A. Galvan, Laurie Huynh, My Joshi, Prasad Cepeda, Carlos Levine, Michael S. |
author_sort | Chen, Jane Y. |
collection | PubMed |
description | This report represents a detailed description of experiments designed to replicate and extend the findings of a published study on the effects of treating the R6/2 Huntington’s disease (HD) mouse model with ~300 CAG repeats using the pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi 4b (Thomas et al., 2008). In addition to testing the R6/2 mice, similar experiments examined the effects of the drug on a second transgenic HD mouse model, the N171-82Q mice. As in the original study, the drug was delivered in the drinking water. In the present study we tested larger groups of mice than in the original study. The results indicated that we were unable to replicate the significant behavioral effects of oral HDACi 4b treatment in the R6/2 mice. There were however, non-significant trends for the treated R6/2 mice to be less affected on some of the measures and there were instances of phenotype progression being delayed in these treated mice. In contrast, we did replicate the protection from striatal atrophy in the R6/2 mice. We also did not observe any beneficial effects of HDACi 4b treatment in the N171-82Q mice. Although the behavioral procedures were replicated and an automated activity assessment was added, there were several unexpected complications in terms of solubility of the drug, CAG repeat length differences and gender differences in progression of the phenotype that could have affected outcomes. Clearly more studies will have to be performed using other methods of delivery as well as assessing effects in more slowly progressing HD models to better evaluate the effects of this HDAC inhibitor. |
format | Online Article Text |
id | pubmed-3574864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35748642013-02-22 Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease Chen, Jane Y. Wang, Elizabeth A. Galvan, Laurie Huynh, My Joshi, Prasad Cepeda, Carlos Levine, Michael S. PLoS Curr Preclinical Therapeutics This report represents a detailed description of experiments designed to replicate and extend the findings of a published study on the effects of treating the R6/2 Huntington’s disease (HD) mouse model with ~300 CAG repeats using the pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi 4b (Thomas et al., 2008). In addition to testing the R6/2 mice, similar experiments examined the effects of the drug on a second transgenic HD mouse model, the N171-82Q mice. As in the original study, the drug was delivered in the drinking water. In the present study we tested larger groups of mice than in the original study. The results indicated that we were unable to replicate the significant behavioral effects of oral HDACi 4b treatment in the R6/2 mice. There were however, non-significant trends for the treated R6/2 mice to be less affected on some of the measures and there were instances of phenotype progression being delayed in these treated mice. In contrast, we did replicate the protection from striatal atrophy in the R6/2 mice. We also did not observe any beneficial effects of HDACi 4b treatment in the N171-82Q mice. Although the behavioral procedures were replicated and an automated activity assessment was added, there were several unexpected complications in terms of solubility of the drug, CAG repeat length differences and gender differences in progression of the phenotype that could have affected outcomes. Clearly more studies will have to be performed using other methods of delivery as well as assessing effects in more slowly progressing HD models to better evaluate the effects of this HDAC inhibitor. Public Library of Science 2013-02-05 /pmc/articles/PMC3574864/ /pubmed/23437422 http://dx.doi.org/10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202 Text en © 2017 Chen, Wang, Galvan, Huynh, Joshi, Cepeda, Levine, et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Preclinical Therapeutics Chen, Jane Y. Wang, Elizabeth A. Galvan, Laurie Huynh, My Joshi, Prasad Cepeda, Carlos Levine, Michael S. Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title_full | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title_fullStr | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title_full_unstemmed | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title_short | Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease |
title_sort | effects of the pimelic diphenylamide histone deacetylase inhibitor hdaci 4b on the r6/2 and n171-82q mouse models of huntington’s disease |
topic | Preclinical Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574864/ https://www.ncbi.nlm.nih.gov/pubmed/23437422 http://dx.doi.org/10.1371/currents.hd.ec3547da1c2a520ba959ee7bf8bdd202 |
work_keys_str_mv | AT chenjaney effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT wangelizabetha effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT galvanlaurie effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT huynhmy effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT joshiprasad effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT cepedacarlos effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease AT levinemichaels effectsofthepimelicdiphenylamidehistonedeacetylaseinhibitorhdaci4bonther62andn17182qmousemodelsofhuntingtonsdisease |